Literature DB >> 8655154

A novel sequence polymorphism in the promoter region of the human B2-bradykinin receptor gene.

A Braun1, E Maier, S Kammerer, B Müller, A A Roscher.   

Abstract

The distribution of a nucleotide polymorphism in the core promoter of the human B2-bradykinin receptor gene was examined in the population of southern Germany. The allelic frequencies were 0.595 for C allele and 0.405 for the T allele. The allele frequencies were in Hardy-Weinberg equilibrium. This new marker provides a valuable tool to assess the risk for putative bradykinin-associated disorders with genetic determinism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8655154     DOI: 10.1007/bf02281884

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  5 in total

1.  A test based on the exact probability distribution of the chi 2 statistic--incorporation into the MASC method.

Authors:  B Müller; F Clerget-Darpoux
Journal:  Ann Hum Genet       Date:  1991-01       Impact factor: 1.670

2.  The human bradykinin B2 receptor gene: full length cDNA, genomic organization and identification of the regulatory region.

Authors:  S Kammerer; A Braun; N Arnold; A A Roscher
Journal:  Biochem Biophys Res Commun       Date:  1995-06-06       Impact factor: 3.575

3.  Identification of polymorphic sites of the human bradykinin B2 receptor gene.

Authors:  A Braun; S Kammerer; E Böhme; B Müller; A A Roscher
Journal:  Biochem Biophys Res Commun       Date:  1995-06-06       Impact factor: 3.575

4.  Genes, hypertension, and cardiac hypertrophy.

Authors:  K Lindpaintner
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

5.  Population study of a sequence polymorphism in intron 2 of the human beta-globin gene.

Authors:  A Braun; H Ambach; R Bichlmaier; S Kammerer; A A Roscher
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

  5 in total
  8 in total

Review 1.  Kinin receptors.

Authors:  F Marceau; D R Bachvarov
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril.

Authors:  P S Silva; V Fontana; M R Luizon; R Lacchini; W A Silva; C Biagi; J E Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

3.  Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema.

Authors:  Murat Bas; Thomas K Hoffmann; Bernd Tiemann; Vu Thao-Vi Dao; Christos Bantis; Vera Balz; Hans-Jürgen Schultz-Coulon; Thomas Stark; Patrick Schuler; Jens Greve; Katrin Ivens; Henning Bier; Georg Kojda
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

4.  The renin angiotensin system and the metabolic syndrome.

Authors:  Chih-Hong Wang; Feng Li; Nobuyuki Takahashi
Journal:  Open Hypertens J       Date:  2010

Review 5.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

6.  Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.

Authors:  Gary P Van Guilder; Mias Pretorius; James M Luther; J Brian Byrd; Kevin Hill; James V Gainer; Nancy J Brown
Journal:  Hypertension       Date:  2008-01-07       Impact factor: 10.190

7.  Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans.

Authors:  Retsilisitsoe R Moholisa; Brian R Rayner; E Patricia Owen; Sylva L U Schwager; Joalice S Stark; Motassim Badri; Clint L Cupido; Edward D Sturrock
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

8.  Bradykinin β2 receptor -58T/C gene polymorphism and essential hypertension: a meta-analysis.

Authors:  Yan-yan Li; Hui Zhang; Jian Xu; Yun Qian; Xin-zheng Lu; Bing Yang; Minglong Chen; Zhi-jian Yang; Ke-jiang Cao
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.